Get started

Financials · HUMA

Humacyte Inc. (HUMA) financials

For the twelve months ended Jun 30, 2026, Humacyte Inc. reported $2.12M of revenue and -$96.73M of net income.

Revenue, TTM
$2.12M
Revenue growth, YoY
+159.3%
Net income, TTM
-$96.73M
Net margin
-4560.8%
Free cash flow, TTM
-$97.56M
Cash
$79.90M
Total debt
$36.32M
P/S
60.01
Market cap
$127.3M
Annual revenue$2.04M
FY2024FY2025
Annual net income-$40.83M
FY2020FY2025
Annual free cash flow-$105.93M
FY2020FY2025

HUMA revenue and earnings growth

HUMA revenueQ2 2026$406.0K

Quarter YoY
+34.9%
QoQ
-18.0%

HUMA revenue was $406.0K in fiscal Q2 2026 (ended Jun 30, 2026), up 34.9% from a year earlier and down 18.0% from the prior quarter. For the full fiscal 2025 it was $2.04M, compared with $0 in fiscal 2024.

HUMA net incomeQ2 2026-$36.80M

HUMA net income was -$36.80M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$37.66M a year earlier. For the full fiscal 2025 it was -$40.83M, compared with -$148.70M in fiscal 2024.

HUMA EPSQ2 2026-$0.16

HUMA diluted EPS was -$0.16 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$0.26, compared with -$1.26 in fiscal 2024.

HUMA free cash flowQ2 2026-$22.16M

HUMA free cash flow was -$22.16M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$26.98M a year earlier. For the full fiscal 2025 it was -$105.93M, compared with -$99.69M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
Revenue$2.04M$0----
Cost of revenue$9.70M$0----
Gross profit-$7.66M$0----
Research and development$69.30M$88.60M$76.55M$63.26M$61.34M$54.08M
Selling, general and admin$31.17M$25.80M$23.50M$22.88M$21.13M$12.01M
Operating income-$108.14M-$114.40M-$100.05M-$84.58M-$81.21M-$64.60M
Interest expense$11.25M$9.28M$6.60M$6.20M$4.35M$2.20M
Pre-tax income-$40.83M-----
Income tax$0$0$0$0$0$0
Net income-$40.83M-$148.70M-$110.78M-$11.96M-$26.48M-$66.52M
EPS, basic-$0.26-$1.26-$1.07-$0.12-$0.66-$11.54
EPS, diluted-$0.26-$1.26-$1.07-$0.12-$0.66-$11.54
Diluted shares158.2M118.5M103.4M103.1M40.0M5.8M

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
Cash and equivalents$50.50M$95.29M$80.80M$149.77M$217.50M$39.93M
Short-term investments--$0$2.11M$8.00M$0
Receivables$441.0K$0$0$31.0K$176.0K$113.0K
Inventory$13.59M$0----
Current assets$67.80M$47.86M$83.28M$154.21M$229.34M$41.45M
Total assets$116.37M$137.87M$128.22M$204.30M$286.53M$106.69M
Current liabilities$18.37M$19.95M$18.44M$19.58M$11.05M$11.23M
Total debt$35.44M$0--$30.00M-
Total liabilities$113.26M$190.54M$114.68M$87.37M$164.36M$36.02M
Shareholders' equity$3.11M-$52.67M$13.55M$116.93M$122.17M-$350.32M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
Operating cash flow-$105.04M-$98.12M-$73.31M-$71.13M-$81.19M-$55.57M
Capital expenditures$884.0K$1.57M$2.28M$1.05M$220.0K$318.0K
Free cash flow-$105.93M-$99.69M-$75.58M-$72.18M-$81.41M-$55.89M
Investing cash flow-$884.0K-$1.57M-$173.0K$4.84M-$8.22M-$268.0K
Financing cash flow$61.49M$114.18M$4.51M-$1.45M$266.98M$2.05M
Stock-based compensation$9.75M$6.14M$6.83M$6.18M$10.15M$4.69M

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
Gross margin-376.1%-----
Operating margin-5306.0%-----
Net margin-2003.6%-----
Free cash flow margin-5197.5%-----
Return on equity-1313.4%--817.8%-10.2%-21.7%-
Return on assets-35.1%-107.9%-86.4%-5.9%-9.2%-62.4%
Current ratio3.692.404.527.8820.753.69
Debt to equity11.40---0.25-

Source: XBRL data Humacyte Inc. files with the SEC, latest filing dated Aug 12, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

HUMA peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
HUMA$2.12M+159.3%-$96.73M-4560.8%$127.3M
AMGN$38.90B+8.2%$9.39B24.1%$251.65B
GILD$30.99B+6.5%-$3.86B-12.5%$210.01B
MRNA$2.52B+13.1%-$2.79B-110.5%$107.39B
ARGX$4.25B+88.6%$1.29B30.4%$59.72B
RVMD$0--$1.13B-$43.29B
BIIB$10.30B+2.3%$347.50M3.4%$37.67B
BNTX€2.87B+4.3%-€1.14B-39.6%$21.98B
EXEL$2.50B+9.1%$885.14M35.5%$17.51B

HUMA FAQ

7 questions
  • What is HUMA revenue?
    Humacyte Inc. (HUMA) reported $2.12M of revenue for the twelve months ended Jun 30, 2026. That is up 159.3% from the year before. Revenue for fiscal 2025 was $2.04M.
  • Is HUMA profitable?
    No. Humacyte Inc. reported a net loss of $96.73M for the twelve months ended Jun 30, 2026.
  • How much cash and debt does HUMA have?
    Humacyte Inc. reported $79.90M in cash and cash equivalents and $36.32M of debt on its most recent balance sheet in SEC filings.
  • What is HUMA gross margin?
    Humacyte Inc.'s gross profit was -$10.49M on $2.12M of revenue for the twelve months ended Jun 30, 2026, a gross margin of -494.6%.
  • What is HUMA free cash flow?
    Humacyte Inc. generated -$97.56M of free cash flow for the twelve months ended Jun 30, 2026, which is operating cash flow of -$97.19M less capital expenditures.
  • When did HUMA last report financial results?
    The latest statements here come from Humacyte Inc.'s 10-Q filed on Aug 12, 2026, covering the period ended Jun 30, 2026.
  • Where does this HUMA financial data come from?
    Quantisnow builds these statements from the structured XBRL data Humacyte Inc. files with the SEC. It is provided for information only and is not investment advice.